Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents
JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)
DOI: 10.1093/jacamr/dlag089 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 27.05.2026. Verfasst von Katherine S Klamer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Thomas Mackey Center for Infectious Disease Research, Henry Ford St.John Hospital, Grosse Pointe Woods, MI, USA. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thomas Mackey Center for Infectious Disease Research, Henry Ford St. John Hospital, Department of Medicine.
Abstract (Originalsprache)
Background
Candidozyma auris (C. auris) is a resistant fungal pathogen with high mortality.
Objectives
To evaluate the in vitro activity of 11 antifungal agents against C. auris from multiple hospitals.
Methods
MIC was determined by microdilution testing for amphotericin B, anidulafungin, caspofungin, manogepix, micafungin, rezafungin and five triazoles. Sanger sequencing was performed on one echinocandin resistant isolate.
Results
There were 84 C. auris isolates from Michigan that were compared with 27 organisms from external sources. Manogepix had the lowest MIC90 (0.03 mg/L). The next most active agent was micafungin. The echinocandins demonstrated a 98.8% susceptibility. A single isolate was found to have a S639F mutation. Amphotericin B demonstrated a 97.6% susceptibility. The MIC90 demonstrated values of ≤0.5 mg/L for isavuconazole, itraconazole and posaconazole. When separating by colonization versus infection isolates, the MIC90 values were identical for all agents, except micafungin, which showed 0.25 versus 0.12 mg/L, respectively. When comparing the reference isolates with Michigan isolates, the MIC90 was identical for echinocandins and manogepix. Differences noted were with amphotericin B, for which 85.2% were susceptible for reference isolates compared to 97.6% from Michigan isolates, and fluconazole, where 25.9% were susceptible for the reference isolates compared with 4.8% from Michigan isolates.
Conclusions
Manogepix and echinocandins demonstrated the greatest activity against C. auris irrespective of hospital and were like the reference isolates. Amphotericin B demonstrated greater activity compared with published studies. Fluconazole has poor activity; the activity of other triazoles remains unclear.
Autor:innen und Institutionen
- Thomas Mackey Center for Infectious Disease Research, Henry Ford St.John Hospital, Grosse Pointe Woods, MI, USA.
- Collage of Medicine, Central Michigan University College of Medicine, Mt. Pleasant, MI, USA.
- School of Medicine, Wayne State University School of Medicine, Detroit, MI, USA.
Förderung
- Thomas Mackey Center for Infectious Disease Research
- Henry Ford St. John Hospital
- Department of Medicine
Zitieren
APA
Klamer, K. S., Bhargava, A., Johnson, L., Sharma, M., & Saravolatz, L. D. (2026). Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag089
Vancouver
Klamer KS, Bhargava A, Johnson L, Sharma M, Saravolatz LD. Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag089
BibTeX
@article{Klamer2026,
author = {Klamer, Katherine S and Bhargava, Ashish and Johnson, Leonard and Sharma, Mamta and Saravolatz, Louis D},
title = {Candidozyma auris susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/jacamr/dlag089}
}
EUVIMED